Trump warns of pharma sector tariff at levels ‘never seen before’, says announcement can be expected soon

Just moments after announcing sweeping reciprocal tariffs on countries that trade with the United States, US President Donald Trump assured that the pharma sector, particularly, is being looked at as a separate category. While speaking to reporters on Air Force One, Trump said, “Pharma tariffs are going to come in at levels you haven’t really seen before. We are looking at pharmaceuticals as a separate category. We will be announcing that sometime in the near-future and not too distant future. It’s under review right now.”

Earlier on Thursday, the US president imposed a 26 per cent reciprocal tariff on India, claiming that the country imposes a 52 per cent duty on American imports and also engaged in currency manipulation and non-tariff barriers. Trump had exempted imports of pharmaceuticals, energy and certain minerals in his reciprocal tariffs. “Some goods will not be subject to the Reciprocal Tariff. These include: (1) articles subject to 50 USC 1702(b); (2) steel/aluminum articles and autos/auto parts already subject to Section 232 tariffs; (3) copper, pharmaceuticals, semiconductors, and lumber articles; (4) all articles that may become subject to future Section 232 tariffs; (5) bullion; and (6) energy and other certain minerals that are not available in the United States,” the White House had said in a factsheet.

However, experts and analysts had maintained that the announcement needs to be seen with caution. Manish Goel, Founder and MD, Equentis Wealth Advisory Services, said, “The exemption of key Indian exports such as pharmaceuticals, semiconductors, and certain minerals from reciprocal tariffs under Section 232 is a relief. However, these exemptions should be viewed with caution.”

“Policy shifts remain a possibility, particularly in high-value and strategically significant industries, eg. pharmaceuticals deemed essential, may still face scrutiny, with potential tariff adjustments on certain drug categories,” he added.

Indian pharma companies had surged on Thursday after Trump had exempted the sector from any levy. However, its now clear that this is only a temporary exemption.

India imports pharma products worth nearly $800 million from the US, while exports to the country are worth $8.7 billion.

Related Posts

  • Pharma
  • June 6, 2025
  • 170 views
Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Mumbai-based pharma major Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug…

  • Pharma
  • June 6, 2025
  • 108 views
Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

In a joint crackdown, Odisha’s Drugs Control administration and Crime Branch Special Task Force (STF) raided Unit-1 Market in Bhubaneswar on Thursday, seizing duplicate cosmetic products sold under top brand…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

Fake cosmetics racket busted in Bhubaneswar’s Unit-1 Market

Illegally stocked drugs worth Rs 5.21 lakh seized

Illegally stocked drugs worth Rs 5.21 lakh seized

Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions

Patanjali and AIIMS Bhopal partner to develop holistic treatment solutions